Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation–positive melanoma

•The combination of atezolizumab, vemurafenib, and cobimetinib seems most beneficial in patients with elevated LDH and PD-L1– tumors.•LDH remains the primary predictor of outcomes regardless of treatment.•IFN-γ and TMB further differentiate outcomes for patients treated with triplet combination therapy.•Patients with normal LDH and high IFN-γ gene signature have the most favorable outcomes on triplet combination therapy.